- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00102921
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn's Disease
Study Overview
Detailed Description
CCX282-B is being developed as a treatment for inflammatory bowel diseases such as Crohn's Disease. CCX282-B is a highly potent, orally active, chemokine receptor antagonist whose single target is the G-protein coupled receptor CCR9. The CCR9 receptor is expressed by most T-cells in the thymus as well as in the intestine, and by a small population of T-cells in the peripheral blood. In humans, the CCR9 receptor is implicated in Crohn's Disease and ulcerative colitis.
Crohn's Disease is an autoimmune disease involving the entire length of the gastrointestinal tract, but with most manifestations in the terminal small intestine and colon. This condition is characterized by mucosal ulcerations that penetrate deeply into the bowel wall. Sometimes the ulcerative lesions completely penetrate the bowel wall, leading to fistula formation and infectious complications requiring surgical intervention. Patients experience considerable lifestyle disruption and disability from this disease, including diarrhea, abdominal pain, malnutrition, anemia, and repetitive surgeries to remove disease-affected gastrointestinal segments.
ChemoCentryx Protocol CL003_282 is a double-blind, placebo-controlled, parallel group, two stratum, Phase 2A pilot study of the safety, tolerability, immunologic and clinical activity, and population pharmacokinetics of a single dose level of CCX282-B administered daily for four consecutive weeks to patients with active, moderate to severe Crohn's Disease. The primary immunologic and clinical activity objective of this study is to provide pilot information regarding the immunologic and clinical activity of daily oral doses of CCX282-B in the treatment of moderate to severe Crohn's Disease, based on changes in the Crohn's Disease Activity Index (CDAI). Secondary immunologic and clinical activity objectives include evaluation of the effect of CCX282-B on the Inflammatory Bowel Disease Questionnaire (IBDQ) instrument, C-reactive protein (CRP), the endoscopic appearance and biopsy of the colon and terminal ileum, and markers of leukocyte subsets and activation status. The primary safety objective of this study is to evaluate the safety and tolerability of oral doses of CCX282-B in patients with moderate to severe Crohn's Disease. In addition, blood samples will be collected for evaluation of the population pharmacokinetics of CCX282-B.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Colorado
-
Golden, Colorado, United States, 80104
- Rocky Mountain Clincal Research
-
Littleton, Colorado, United States, 80120
- Arapahoe Gastroenterology
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Atlanta Gastroenterology Associates
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Minnesota
-
Rochester, Minnesota, United States
- Mayo Clinic Rochester
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Comprehensive Clinical Research
-
-
New York
-
Great Neck, New York, United States, 11021
- Long Island Clinical Research Associates, LLP
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Wake Forest Research
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-5066
- University Hospitals of Cleveland, Div of Gastroenterology
-
-
Tennessee
-
Jackson, Tennessee, United States, 38305
- Digestive Disease Clinic
-
Nashville, Tennessee, United States, 37205
- Nashville Medical Research Institute
-
-
Utah
-
Salt Lake City, Utah, United States, 84124
- Center for Colon Rectal Disease
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia Health System, Digestive Health Center of Excellence
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of moderate to severe Crohn's Disease in small intestine; disease must be active at the time of study entry
- Use of adequate and approved methods of birth control throughout the study period
- Willing and able to sign an informed consent
Exclusion Criteria:
- Pregnant or breastfeeding
- Infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV; the virus that causes AIDS)
- Abuse of alcohol or of illegal drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Crohn's Disease Activity Index score
|
Safety (Adverse Events, tolerability)
|
Secondary Outcome Measures
Outcome Measure |
---|
C-reactive protein
|
Inflammatory Bowel Disease Questionnaire
|
Endoscopic appearance and biopsy of colon and terminal ileum
|
Markers of leukocyte subsets and activation status
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: MD, Amgen
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL003_282
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on CCX282-B
-
ChemoCentryxCompletedCrohn's DiseaseBrazil, Australia, Israel, Belgium, France, Canada, Germany, Denmark, Hungary, Bulgaria, Sweden, Netherlands, Austria, Poland, South Africa, United Kingdom, Czechia
-
ChemoCentryxCompleted
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
National Institute of Allergy and Infectious Diseases...Dynavax Technologies CorporationActive, not recruitingHIV Infection | Hepatitis BUnited States, Haiti, Botswana, Philippines, Thailand, Brazil, Kenya, Malawi, India, South Africa, Uganda, Vietnam
-
Indiana UniversityAlcon ResearchCompleted
-
PfizerCompletedA Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804Healthy VolunteersBelgium
-
Marya Strand, MDCompletedRespiratory Distress SyndromeUnited States
-
ChemoCentryxMedpace, Inc.CompletedFocal Segmental Glomerulosclerosis | FSGS | GlomerulosclerosisUnited States, France, Italy, Australia, United Kingdom, Canada, New Zealand, Poland
-
Soroka University Medical CenterCompletedInflammatory Bowel DiseaseIsrael
-
Epstein, Arthur B., OD, FAAOAlcon ResearchCompleted